Eli Lilly and Company
Anti-N3pGlu amyloid beta peptide antibodies and uses thereof

Abstract:

The invention is directed to a short term induction treatment with anti-N3pGlu A.beta. antibodies of a disease characterized by deposition of A.beta. in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu A.beta. antibody for a period of 6 months or less.